

# Anders sberg

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2695407/anders-asberg-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

216  
papers

5,905  
citations

40  
h-index

70  
g-index

241  
ext. papers

7,036  
ext. citations

4  
avg, IF

5.51  
L-index

#	Paper	IF	Citations
216	Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. <i>Transplantation</i> , <b>2013</b> , 96, 333-60	1.8	577
215	International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. <i>Transplantation</i> , <b>2010</b> , 89, 779-95	1.8	447
214	Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. <i>American Journal of Transplantation</i> , <b>2007</b> , 7, 2106-13	8.7	317
213	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
212	Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 1205-13	8.7	135
211	The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary. <i>CKJ: Clinical Kidney Journal</i> , <b>2018</b> , 11, 108-122	4.5	126
210	Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 2236-43	8.7	116
209	Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. <i>American Journal of Transplantation</i> , <b>2001</b> , 1, 382-6	8.7	111
208	Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 1499-504	4	108
207	Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 532-9	6.1	99
206	Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. <i>Drugs</i> , <b>2003</b> , 63, 367-78	12.1	94
205	Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. <i>European Journal of Pharmaceutical Sciences</i> , <b>2008</b> , 33, 317-25	5.1	90
204	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 685-93	2.8	84
203	Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. <i>Transplantation</i> , <b>2011</b> , 92, 217-23	1.8	84
202	Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 1160-6	11.6	81
201	The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 702-720	4.5	78
200	Importance of hematocrit for a tacrolimus target concentration strategy. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 65-77	2.8	72

199	The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. <i>Transplantation</i> , <b>2011</b> , 91, 231-6	1.8	72
198	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 697-704	1.6	69
197	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 655-61	4	65
196	Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. <i>American Journal of Transplantation</i> , <b>2010</b> , 10, 1881-8	8.7	65
195	An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 374-81	8.7	64
194	Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 926-33	4.3	62
193	Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 275-82	6.1	62
192	Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1546-53	11.6	61
191	Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 311-8	6.1	61
190	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. <i>Transplantation</i> , <b>2015</b> , 99, 2158-66	1.8	60
189	Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 204-12	8.7	60
188	Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. <i>Diabetes Care</i> , <b>2019</b> , 42, 1067-1074	14.6	58
187	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 509-23	3.8	58
186	Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. <i>Transplantation</i> , <b>2008</b> , 85, 179-84	1.8	53
185	Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. <i>Transplant International</i> , <b>2013</b> , 26, 1198-207	3	51
184	The European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2014: a summary. <i>CKJ: Clinical Kidney Journal</i> , <b>2017</b> , 10, 154-169	4.5	50
183	Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 388-91	6.1	49
182	Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 413-8	4.3	45

181	Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , <b>2002</b> , 58, 515-20	2.8	45
180	Atorvastatin improves endothelial function in renal-transplant recipients. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 1920-4	4.3	45
179	Exposure to Mycophenolate and Fatherhood. <i>Transplantation</i> , <b>2017</b> , 101, e214-e217	1.8	44
178	A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation. <i>American Journal of Transplantation</i> , <b>2012</b> , 12, 3316-25	8.7	43
177	Nonspecific microvascular vasodilation during iontophoresis is attenuated by application of hyperosmolar saline. <i>Microvascular Research</i> , <b>1999</b> , 58, 41-8	3.7	43
176	New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , <b>2014</b> , 18, 103-11	1.8	40
175	Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. <i>Transplantation</i> , <b>2008</b> , 86, 1379-83	1.8	40
174	Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. <i>Transplantation</i> , <b>2006</b> , 82, 62-8	1.8	38
173	Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. <i>Nephrology Dialysis Transplantation</i> , <b>2003</b> , 18, 1899-908	4.3	37
172	Pulmonary hemodynamics and plasma endothelin-1 during hypoxemia and reoxygenation with room air or 100% oxygen in a piglet model. <i>Pediatric Research</i> , <b>1998</b> , 44, 843-9	3.2	37
171	The ERA-EDTA Registry Annual Report 2017: a summary. <i>CKJ: Clinical Kidney Journal</i> , <b>2020</b> , 13, 693-709	4.5	35
170	Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients. <i>Transplantation</i> , <b>2015</b> , 99, 1730-7	1.8	34
169	Cinacalcet effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 1048-53	4.3	34
168	Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. <i>Transplantation</i> , <b>2015</b> , 99, 528-32	1.8	33
167	Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 87, 699-705	6.1	33
166	New-onset posttransplantation diabetes mellitus: insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. <i>Current Diabetes Reviews</i> , <b>2005</b> , 1, 1-10	2.7	33
165	Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. <i>Drug Metabolism and Disposition</i> , <b>2002</b> , 30, 1-3	4	33
164	The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review. <i>Obesity Reviews</i> , <b>2019</b> , 20, 1299-1311	10.6	32

163	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. <i>Biochemical Pharmacology</i> , <b>2011</b> , 82, 1219-26	6	32
162	Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 852, 345-52	3.2	32
161	The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 1743-9	4.3	32
160	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 617-24	14.6	31
159	Analysis and clinical correlation of genetic variation in cytomegalovirus. <i>Transplant Infectious Disease</i> , <b>2012</b> , 14, 132-40	2.7	31
158	CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. <i>European Journal of Clinical Pharmacology</i> , <b>2000</b> , 56, 575-9	2.8	28
157	High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. <i>Transplantation</i> , <b>2017</b> , 101, e273-e279	1.8	27
156	Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout ( <i>Oncorhynchus mykiss</i> ) hepatocytes. <i>Toxicology in Vitro</i> , <b>2010</b> , 24, 1610-8	3.6	27
155	The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 38-45	3.2	27
154	Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies. <i>Transplantation</i> , <b>2017</b> , 101, 1410-1415	1.8	25
153	Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2013</b> , 27, 2094-101	5.2	25
152	Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , <b>1999</b> , 55, 383-7	2.8	24
151	Limitations of hemoglobin A1c for the diagnosis of posttransplant diabetes mellitus. <i>Transplantation</i> , <b>2015</b> , 99, 629-35	1.8	23
150	Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. <i>Transplant International</i> , <b>2016</b> , 29, 568-78	3	23
149	Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. <i>Transplant International</i> , <b>2015</b> , 28, 1162-71	3	22
148	Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 1465-70	4.3	21
147	Hcmv-miR-UL22A-5p: A Biomarker in Transplantation With Broad Impact on Host Gene Expression and Potential Immunological Implications. <i>American Journal of Transplantation</i> , <b>2015</b> , 15, 1893-902	8.7	20
146	Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. <i>Basic Research in Cardiology</i> , <b>2002</b> , 97, 239-47	11.8	20

145	Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. <i>Pharmacological Research</i> , <b>2018</b> , 130, 316-321	10.2	19
144	Outcomes in Pancreas Transplantation With Exocrine Drainage Through a Duodenoduodenostomy Versus Duodenojejunostomy. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 154-162	8.7	19
143	Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients. <i>Transplantation Research</i> , <b>2012</b> , 1, 9		19
142	The ERA-EDTA Registry Annual Report 2018: a summary. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 107-123	4.5	19
141	Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 607-614	3.2	19
140	A drug safety evaluation of everolimus in kidney transplantation. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 1013-22	4.1	18
139	Associations Between Posttransplantation Diabetes Mellitus and Renal Graft Survival. <i>Transplantation</i> , <b>2017</b> , 101, 1282-1289	1.8	17
138	Evaluation of organic anion-transporting polypeptide 1B1 and CYP3A4 activities in primary human hepatocytes and HepaRG cells cultured in a dynamic three-dimensional bioreactor system. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 343, 145-56	4.7	17
137	A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 615-23	6.2	17
136	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 150-200	3.2	17
135	Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 693-702	6.2	16
134	Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. <i>Clinical Transplantation</i> , <b>2009</b> , 23, 511-8	3.8	16
133	Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2007</b> , 43, 1039-44	3.5	16
132	A simple and sensitive high-performance liquid chromatography assay of diltiazem and main metabolites in renal transplanted patients. <i>Clinica Chimica Acta</i> , <b>1999</b> , 283, 63-75	6.2	16
131	The CYP3A biomarker 4βhydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1457-1465	3.8	15
130	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. <i>Molecular Diagnosis and Therapy</i> , <b>2013</b> , 17, 233-7	4.5	15
129	More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. <i>Transplantation</i> , <b>2014</b> , 97, 1266-71	1.8	15
128	Fluvastatin and fluvastatin extended release: a clinical and safety profile. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 641-52	2.5	15

127	Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients. <i>Microvascular Research</i> , <b>2000</b> , 60, 81-90	3.7	15
126	Immunosuppression and Reproductive Health After Kidney Transplantation. <i>Transplantation</i> , <b>2019</b> , 103, e325-e333	1.8	15
125	First Scandinavian Protocol for Controlled Donation After Circulatory Death Using Normothermic Regional Perfusion. <i>Transplantation Direct</i> , <b>2018</b> , 4, e366	2.3	15
124	Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. <i>Clinical Transplantation</i> , <b>1998</b> , 12, 553-6	3.8	15
123	A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity. <i>Drug Metabolism and Disposition</i> , <b>2020</b> , 48, 8-17	4	14
122	Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1154-60	11.6	14
121	Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy. <i>Molecular Diagnosis and Therapy</i> , <b>2011</b> , 15, 221-7	4.5	14
120	Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. <i>Clinical Transplantation</i> , <b>2003</b> , 17, 385-90	3.8	14
119	Evaluation of tools for annual capture of adherence to immunosuppressive medications after renal transplantation - a single-centre open prospective trial. <i>Transplant International</i> , <b>2019</b> , 32, 614-625	3	13
118	Inflammatory and related biomarkers are associated with post-transplant diabetes mellitus in kidney recipients: a retrospective study. <i>Transplant International</i> , <b>2018</b> , 31, 510-519	3	12
117	Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population. <i>Transplantation Direct</i> , <b>2017</b> , 3, e332	2.3	12
116	Endothelial dysfunction is associated with graft loss in renal transplant recipients. <i>Transplantation</i> , <b>2013</b> , 95, 733-9	1.8	12
115	Treatment of cytomegalovirus disease in solid organ transplant recipients: markers of inflammation as predictors of outcome. <i>Transplantation</i> , <b>2012</b> , 94, 1060-5	1.8	12
114	2-D hydrophilic interaction liquid chromatography-RP separation in urinary proteomics--minimizing variability through improved downstream workflow compatibility. <i>Journal of Separation Science</i> , <b>2010</b> , 33, 864-72	3.4	12
113	Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 152-8	3.2	12
112	Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation. <i>BMC Nephrology</i> , <b>2019</b> , 20, 12	2.7	12
111	Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. <i>European Journal of Clinical Nutrition</i> , <b>2016</b> , 70, 824-30	5.2	11
110	Secreted Wnt antagonists during eradication of cytomegalovirus infection in solid organ transplant recipients. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 210-5	8.7	11

109	Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial. <i>Clinical Transplantation</i> , <b>2013</b> , 27, E151-6	3.8	11
108	No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 3767-72	4.3	11
107	Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial. <i>Addiction</i> , <b>2019</b> , 114, 859-867	4.6	11
106	High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. <i>Transplant International</i> , <b>2019</b> , 32, 257-269	3	11
105	Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 110, 432-437	3.9	11
104	Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 675-80	3.2	10
103	Low level of MAP44, an inhibitor of the lectin complement pathway, and long-term graft and patient survival; a cohort study of 382 kidney recipients. <i>BMC Nephrology</i> , <b>2016</b> , 17, 148	2.7	9
102	Association between insulin resistance and endothelial dysfunction in renal transplant recipients. <i>Clinical Transplantation</i> , <b>2006</b> , 20, 195-9	3.8	9
101	Global variability analysis of mRNA and protein concentrations across and within human tissues. <i>NAR Genomics and Bioinformatics</i> , <b>2020</b> , 2, lqz010	3.7	9
100	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 407-414	3.2	9
99	Collectin Liver 1 and Collectin Kidney 1 of the Lectin Complement Pathway Are Associated With Mortality After Kidney Transplantation. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 265-271	8.7	8
98	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Clinical Pharmacokinetics</i> , <b>2018</b> , 57, 1459-1469	6.2	8
97	Resolution of Calciphylaxis After Urgent Kidney Transplantation in 3 Patients With End-Stage Kidney Failure. <i>Transplantation Direct</i> , <b>2016</b> , 2, e113	2.3	8
96	Visceral fat is strongly associated with post-transplant diabetes mellitus and glucose metabolism 1 year after kidney transplantation. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12869	3.8	8
95	Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. <i>Transplantation</i> , <b>2009</b> , 87, 1221-4	1.8	8
94	Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 790-800	8.7	8
93	Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1. <i>Clinical Transplantation</i> , <b>1998</b> , 12, 363-70	3.8	8
92	Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 292-300	3.2	7



91	The EKITE network (epidemiology in kidney transplantation - a European validated database): an initiative epidemiological and translational European collaborative research. <i>BMC Nephrology</i> , <b>2019</b> , 20, 365	2.7	7
90	Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients. <i>Journal of Renal Nutrition</i> , <b>2017</b> , 27, 161-168	3	7
89	Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 1159-66	4	7
88	Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). <i>BMJ Open</i> , <b>2018</b> , 8, e021878	3	7
87	Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma. <i>PLoS ONE</i> , <b>2013</b> , 8, e60767	3.7	7
86	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. <i>Kidney International Reports</i> , <b>2020</b> , 5, 189-198	4.1	7
85	Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!. <i>Transplantation</i> , <b>2021</b> , 105, e80-e81	1.8	7
84	Accelerated 18O-labeling in urinary proteomics. <i>Journal of Chromatography A</i> , <b>2010</b> , 1217, 8241-8	4.5	6
83	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006299	7.6	6
82	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 11-18	3.2	6
81	Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1350-1352	3.8	5
80	Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. <i>Transplant International</i> , <b>2017</b> , 30, 1119-1131	3	5
79	Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience. <i>Nephrology</i> , <b>2016</b> , 21, 821-7	2.2	5
78	Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 762-771	6.1	5
77	Development of Kidney Transplant Fibrosis Is Inversely Associated With Plasma Marine Fatty Acid Level. <i>Journal of Renal Nutrition</i> , <b>2018</b> , 28, 118-124	3	5
76	Vitamin D as a risk factor for patient survival after kidney transplantation: A prospective observational cohort study. <i>Clinical Transplantation</i> , <b>2019</b> , 33, e13517	3.8	4
75	Increased osteoprotegerin predicts poor virological outcome during anticytomegalovirus therapy in solid organ transplant recipients. <i>Transplantation</i> , <b>2015</b> , 99, 100-5	1.8	4
74	Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study. <i>Transplant International</i> , <b>2018</b> , 31, 629-638	3	4

73	Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study. <i>European Journal of Endocrinology</i> , <b>2018</b> , 179, 251-259	6.5	4
72	Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score. <i>BMC Nephrology</i> , <b>2018</b> , 19, 212	2.7	4
71	Uric acid and clinical correlates of endothelial function in kidney transplant recipients. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 1167-76	3.8	4
70	Risk factors for exertional rhabdomyolysis with renal stress. <i>BMJ Open Sport and Exercise Medicine</i> , <b>2017</b> , 3, e000241	3.4	4
69	Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats. <i>European Journal of Medicinal Chemistry</i> , <b>2009</b> , 44, 3874-9	6.8	4
68	Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. <i>Clinical and Translational Science</i> , <b>2020</b> , 13, 1327-1335	4.9	4
67	Complexity of Host Micro-RNA Response to Cytomegalovirus Reactivation After Organ Transplantation. <i>American Journal of Transplantation</i> , <b>2016</b> , 16, 650-60	8.7	4
66	A rapid and sustained improvement of calcification propensity score (serum T) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e13131	3.8	3
65	Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1 year after transplantation. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13196	3.8	3
64	Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 59-62	2.8	3
63	Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1449-1462	6.2	3
62	Prediction of Fat-Free Mass in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 439-46	3.6	3
61	Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 371-375	3.2	3
60	Contraceptive Choices and Counseling in Norwegian Female Renal Transplant Recipients. <i>Transplantation Proceedings</i> , <b>2019</b> , 51, 470-474	1.1	2
59	Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 866-873	6.1	2
58	Individualizing Transplant Therapy <b>2017</b> , 255-279		2
57	Plasma n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Renal Transplant Recipients. <i>Journal of Renal Nutrition</i> , <b>2016</b> , 26, 196-203	3	2
56	Arterial stiffness is associated with visceral fat mass in kidney transplanted patients-A nationwide cohort study. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13341	3.8	2

55	Small effort, high impact: Focus on physical activity improves oxygen uptake (VO <sub>2</sub> ), quality of life, and mental health after pediatric renal transplantation. <i>Pediatric Transplantation</i> , <b>2018</b> , 22, e13242	1.8	2
54	Mycophenolate Acid and Balancing the Risk for Male Allograft Recipients. <i>Transplantation</i> , <b>2017</b> , 101, e39	1.8	2
53	Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation. <i>Vascular Disease Prevention</i> , <b>2006</b> , 3, 229-234		2
52	Gene expression of the renal endothelin system in renal transplant recipients on cyclosporine A based immunosuppression. <i>Transplantation</i> , <b>1999</b> , 67, 1056-60	1.8	2
51	Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 247-255	3.2	2
50	Trans-fatty Acids and Survival in Renal Transplantation. <i>Journal of Renal Nutrition</i> , <b>2019</b> , 29, 169-180	3	2
49	Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20-50 years: a study by the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 534-543	4.3	2
48	Adherence to Immunosuppressive Medications in Renal Transplant Recipients [Different Tools Capture Different Patients. <i>Transplantation</i> , <b>2018</b> , 102, S282	1.8	2
47	Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	2
46	Response to: Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1357-1358	3.8	1
45	Recovery of CYP3A Phenotype after Kidney Transplantation. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 1260-1265	4	1
44	Plasma n-6 Polyunsaturated Fatty Acid Levels and Survival in Renal Transplantation. <i>Journal of Renal Nutrition</i> , <b>2018</b> , 28, 333-339	3	1
43	Quantification of mRNA levels of endothelin receptor subtypes and preproEndothelin-1 in renal needle biopsies by competitive reverse transcriptase polymerase chain reaction. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1998</b> , 58, 299-306	2	1
42	Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	1
41	Cardiovascular remodeling in living kidney donors with reduced glomerular filtration rate: rationale and design of the CENS study. <i>Blood Pressure</i> , <b>2020</b> , 29, 123-134	1.7	1
40	Five decades with grandparent donors: The Norwegian strategy and experience. <i>Pediatric Transplantation</i> , <b>2020</b> , 24, e13751	1.8	1
39	Blood Pressure Treatment in Kidney Transplant Recipients-Can We Improve?. <i>Transplantation Direct</i> , <b>2021</b> , 7, e688	2.3	1
38	Cardiovascular Risk Factors are Inversely Associated With Omega-3 Polyunsaturated Fatty Acid Plasma Levels in Pediatric Kidney Transplant Recipients. <i>Journal of Renal Nutrition</i> , <b>2021</b> , 31, 278-285	3	1

37	Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA Registry. <i>Annals of Epidemiology</i> , <b>2016</b> , 26, 773-779	6.4	1
36	Beyond Survival in Solid Organ Transplantation: A Summary of Expert Presentations from the Sandoz 6th Standalone Transplantation Meeting, 2018. <i>Transplantation</i> , <b>2019</b> , 103, S1-S13	1.8	1
35	Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 2535	3.8	1
34	Changes in clinical indicators related to the transition from dialysis to kidney transplantation-data from the ERA-EDTA Registry. <i>CKJ: Clinical Kidney Journal</i> , <b>2020</b> , 13, 188-198	4.5	1
33	Recovery of kidney function in patients treated with maintenance dialysis-a report from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 1078-1087	4.3	1
32	Preserved Insulin Sensitivity and Kidney Function One Year After Successful Pancreas Transplantation. <i>Transplantation</i> , <b>2018</b> , 102, S751	1.8	1
31	Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence.. <i>Transplant International</i> , <b>2022</b> , 35, 10329	3	1
30	Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 738927	8.4	0
29	Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 1704-1714	6.9	0
28	A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients: A National Prospective Study.. <i>Transplantation Direct</i> , <b>2022</b> , 8, e1307	2.3	0
27	Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera		0
26	Endothelial Dysfunction and 6-Year Risk of Mortality in Kidney Transplant Recipients.. <i>Transplantation Direct</i> , <b>2022</b> , 8, e1262	2.3	0
25	High Plasma Oxalate Levels Early After Kidney Transplantation Are Associated With Impaired Long-Term Outcomes.. <i>Transplant International</i> , <b>2022</b> , 35, 10240	3	0
24	Costimulation Blockade: America First, Canada Second [What About Norway?]. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 2230	8.7	
23	Endothelial function after pancreas transplantation-A single-center observational study. <i>Clinical Transplantation</i> , <b>2020</b> , 34, e13815	3.8	
22	The Authors'Reply. <i>Transplantation</i> , <b>2018</b> , 102, e43-e44	1.8	
21	SP736MARINE N-3 POLYUNSATURATED FATTY ACIDS AND BONE DENSITY IN KIDNEY TRANSPLANTATION: A DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i596-i596	4.3	
20	SP744MARINE n-3 FATTY ACID SUPPLEMENTATION REDUCES PLASMA TRIGLYCERIDES & IMPROVES FLOW MEDIATED DILATATION IN RENAL TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i599-i599	4.3	

19	SP751MARINE n-3 FATTY ACID SUPPLEMENTATION REDUCES INFLAMMATION & PREVENTS RENAL GRAFT FIBROSIS. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i601-i601	4.3
18	How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients. <i>Transplantation</i> , <b>2017</b> , 101, e347	1.8
17	Haptoglobin 2-2 Genotype, Patient, and Graft Survival in Renal Transplant Recipients. <i>Progress in Transplantation</i> , <b>2017</b> , 27, 386-391	1.1
16	Response to letter about intensity of immunosuppressive therapy on outcome of treatment for CMV disease. <i>American Journal of Transplantation</i> , <b>2011</b> , 11, 1103-4	8.7
15	IN VIVO VIRAL MICRORNA PROFILING IN A LARGE COHORT OF TRANSPLANT PATIENTS WITH CMV DISEASE. <i>Transplantation</i> , <b>2010</b> , 90, 27	1.8
14	Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient-No Intervention Actually Needed. <i>Transplantation Direct</i> , <b>2020</b> , 6, e609	2.3
13	Reply to letter: "What about drug bioavailability in patients who had bariatric surgery and dependent on immunosuppressives?". <i>Obesity Reviews</i> , <b>2020</b> , 21, e12954	10.6
12	The AuthorsMReply: Placental Pathology in Pregnancies After Kidney Transplantation. <i>Transplantation</i> , <b>2020</b> , 104, e216	1.8
11	Insulin secretion and action after pancreas transplantation. A retrospective single-center study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2021</b> , 81, 365-370	2
10	Increased systemic exposure of once-daily tacrolimus in renal transplant recipients on marine omega-3 fatty acid supplementation. <i>Transplant International</i> , <b>2021</b> , 34, 1322-1324	3
9	233.4: The Scandinavian exchange program: Ischemic time for imported kidneys in Norway and factors associated with long ischemic time.. <i>Transplantation</i> , <b>2019</b> , 103, S50-S50	1.8
8	Patient selection for islet or solid organ pancreas transplantation: experiences from a multidisciplinary outpatient-clinic approach. <i>Endocrine Connections</i> , <b>2021</b> , 10, 230-239	3.5
7	SP755MARINE n-3 FATTY ACID SUPPLEMENTATION INCREASE TACROLIMUS EXPOSURE IN RENAL TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i603-i603	4.3
6	A Limited Sampling Strategy to Estimate Whole Blood and Intra-lymphocyte Exposure of Everolimus in Renal Transplant Recipients using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Transplantation</i> , <b>2018</b> , 102, S92	1.8
5	High-Dose Fish Oil Supplementation Increase Tacrolimus Exposure in Stable Renal Transplant Recipients. <i>Transplantation</i> , <b>2018</b> , 102, S599	1.8
4	Outcomes of Kidney Transplantation in Former Non Kidney Solid Organ Transplant. <i>Transplantation</i> , <b>2018</b> , 102, S85	1.8
3	High Tacrolimus Clearance □A Risk Factor for Development of Interstitial Fibrosis and Tubular Atrophy in the Transplanted Kidney. <i>Transplantation</i> , <b>2018</b> , 102, S364	1.8
2	Posttransplant Hypertension Matters!. <i>Transplantation</i> , <b>2021</b> , 105, e150	1.8

- 1 Anticoagulation and Safety of Renal Transplant Biopsy.. *Clinical Transplantation*, **2022**, e14715 3.8